Paradigm Biopharmaceuticals Ltd.ASX: PAR

Paradigm Doses First US Subjects under Phase 3 trial

Apr 28, 2022 at 4:11 AM UTC · Issued by Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment